Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Pathology Visions 2026: Connecting Innovation with Purpose
Event Details
Digital pathology is transforming how we diagnose, collaborate, innovate—and ultimately improve patient care. The conversations shaping the future are happening at Pathology Visions 2026, October 16–18 in San Diego.
Join the Digital Pathology Association (DPA) for three days of expert education, meaningful collaboration, and the latest advancements in digital pathology and AI. Connect with more than 1,000 pathologists, researchers, laboratory leaders, healthcare professionals, and industry innovators who are driving the next era of precision medicine.
Under this year’s theme, “Connecting Innovation with Purpose,” Pathology Visions 2026 explores the journey of digital pathology from technical innovation to direct patient impact. Sessions will address real-world clinical applications, AI and patient outcomes, emerging technologies and trends, best practices for integrating digital pathology into clinical workflows, and more.
Attendees will have the opportunity to:
- Gain actionable insights from 100+ visionary speakers
- Explore cutting-edge solutions from 65+ exhibitors
- Discover the latest research through 50+ scientific poster presentations
- Participate in workshops, educational sessions, and networking opportunities
- Connect with leaders and innovators shaping the future of pathology
- Exchange ideas and explore strategies for advancing digital pathology and AI in patient care
Whether you’re looking to gain practical insights, discover emerging technologies, or expand your professional network, #PathVisions26 brings the pathology community together to exchange ideas, spark innovation, forge lasting partnerships, and shape the future of patient care.
Pathology Visions 2026 is an essential event for pathologists, laboratory and healthcare leaders, researchers, and others committed to advancing patient care through the power of digital pathology.
For more information and to register, visit: https://digitalpathologyassociation.org/pathology-visions-conference.
